Advanz Pharma

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

Retrieved on: 
Monday, February 12, 2024
Cornell University, Acquisition, SAN, Sunovion, Merck, Research, Pharmacia & Upjohn, MD, Drug development, Growth, Research and development, University, Ōtsuka, Therapy, Advanz Pharma, Psychiatry, Development, Cell, Medical research, Pharmaceutical industry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.

Key Points: 
  • Dr. Corrigan brings over three decades of life sciences leadership experience to Silver Creek.
  • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.
  • "We are pleased to welcome Dr. Corrigan to lead Silver Creek through its next phase of growth," said Tim Throsby, Silver Creek's Chairman of the Board.
  • "The elegance and innovation behind Silver Creek's Smart Growth Factor™ platform is very compelling, and the pre-clinical data around scp776 is equally impressive.

Applied Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, FDA, Research, Insurance, Harvard Medical School, Heart failure, MAA, Ongo, Treatment, MD, Cardiology, European Medicines Agency, Diabetes, Chairperson, Doctor of Philosophy, ChromeOS, EASD, Quality of life, Symposium, KOL, U.S. FDA, EMA, European Association for the Study of Diabetes, Annual general meeting, NDA, Safety, Therapy, Diabetic cardiomyopathy, Investment, Patient, Advanz Pharma, Pharmaceutical industry, Birth control, SORD, Galactosemia

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • The Company expects topline data from the study in the fourth quarter of 2023.
  • Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics, presented the data in an oral Symposium entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes.
  • Cash and cash equivalents and short-term investments totaled $37.5 million as of September 30, 2023, compared with $30.6 million at December 31, 2022.
  • Net loss for the third quarter of 2023 was $42.4 million, or $0.47 per basic and diluted common share, compared to a net loss of $19.1 million, or $0.40 per basic and diluted common share, for the third quarter 2022.

Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update

Retrieved on: 
Wednesday, August 30, 2023
External commercial borrowing, US Foods, Partnership, Teva, RSU, Adalimumab, Research, Business analyst, R, Patient, Investment, Administration, Advanz Pharma, Webcast, Stada Arzneimittel, Johnson & Johnson, Biosimilar, CRL, Research and development, FDA, Ustekinumab, BLA, Food, Pharmaceutical industry, Flour, Generic drug, Security (finance), G&A

Product Revenue: Product revenue was $22.7 million for the six months ended June 30, 2023, compared to $3.9 million for the same six months of 2022.

Key Points: 
  • Product Revenue: Product revenue was $22.7 million for the six months ended June 30, 2023, compared to $3.9 million for the same six months of 2022.
  • Revenue for the six months ended June 30, 2023 consisted of product revenue from sales of AVT02 in select European countries and Canada.
  • Research and Development (R&D) Expenses: R&D expenses were $99.6 million for the six months ended June 30, 2023, compared to $86.9 million for the same six months of 2022.
  • Alvotech will conduct a business update conference call and live webcast on Thursday, August 31 at 8:00 am ET (12:00 noon GMT).

Applied Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 10, 2023
Insurance, ChromeOS, Sorbitol dehydrogenase, Chairperson, PIP, Journal, New Drug Application, European Medicines Agency, Diabetic cardiomyopathy, NDA, Quality of life, Medicine, Doctor of Philosophy, Brain cell, EMA, INSPIRE, US, Ongo, Galactitol, Phase 3, Patient, Investment, Treatment, Annual general meeting, Advanz Pharma, MAA, Research, FDA, Therapy, ADA, American Diabetes Association, US FDA, Safety, Disease, Pharmaceutical industry, Birth control, Galactosemia, EU, Sorbitol, SORD

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • “In the second quarter we continued to advance our programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy,” said Shoshana Shendelman, PhD, Founder, Chief Executive Officer, and Chair of the Board.
  • In June 2023, the Company presented baseline data at the 2023 Annual Meeting of the ADA from the ongoing Phase 3 ARISE-HF study of AT-001 (caficrestat) in Diabetic Cardiomyopathy (DbCM).
  • The Company expects topline data from the study in the fourth quarter of 2023.
  • Net loss for the second quarter of 2023 was $29.6 million, or $0.37 per basic and diluted common share, compared to a net loss of $25.9 million, or $0.96 per basic and diluted common share, for the second quarter 2022.

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

Retrieved on: 
Tuesday, July 25, 2023
PIP, Galactose, New Drug Application, European Medicines Agency, NDA, Doctor of Philosophy, EMA, US, Galactitol, Patient, Advanz Pharma, MAA, FDA, Therapy, US FDA, Pharmaceutical industry, Galactosemia

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the Galactosemia program, including updates on the regulatory paths for govorestat (AT-007) in both the U.S. and Europe.

Key Points: 
  • NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the Galactosemia program, including updates on the regulatory paths for govorestat (AT-007) in both the U.S. and Europe.
  • “We look forward to advancing our regulatory submissions in both the U.S. and Europe,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
  • “We believe that govorestat offers compelling efficacy alongside a favorable safety profile and represents a transformative treatment option for patients with Galactosemia.
  • There are currently no approved treatments for Galactosemia, and we hope to bring govorestat to patients as the first treatment for Galactosemia as soon as possible.”

Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Wyeth, IPO, Doctor of Philosophy, MBA, BD (company), CareFusion, The Canadian Journal of Economics and Political Science, Accounting, Rutgers University, Advanz Pharma, Convatec, MD, Patient, Mylan, Allegheny College, Knowledge, LOS, Management, Economics, Pfizer

LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.  Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.

Key Points: 
  • Mr. Borkowski joins the Nexcella, Inc. Board of Directors with more than 30 years of experience in the pharmaceutical and healthcare industry, including 7 years as Chief Financial Officer of Mylan N.V.
    Mr. Borkowski is also the former Chief Financial Officer of CareFusion, which was ultimately acquired by Becton Dickinson for $12.2 billion
    LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.
  • Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.
  • After joining Mylan in 2002, Mr. Borkowski held positions of increasing responsibility including Chief Financial Officer and Executive Vice President from 2002 until 2009.
  • In addition to his experience at Mylan, Mr. Borkowski was the former Chief Financial Officer of CareFusion, where he led the IPO.

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

Retrieved on: 
Thursday, June 22, 2023
Wyeth, IPO, Doctor of Philosophy, MBA, BD (company), CareFusion, The Canadian Journal of Economics and Political Science, Accounting, Rutgers University, Advanz Pharma, Convatec, MD, Patient, Mylan, Allegheny College, Knowledge, LOS, Management, Economics, Pfizer

LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, has been appointed to the Company’s Board of Directors.  Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.

Key Points: 
  • Mr. Borkowski brings significant leadership in capital markets, finance, accounting, strategy, and mergers & acquisitions to Nexcella.
  • After joining Mylan in 2002, Mr. Borkowski held positions of increasing responsibility including Chief Financial Officer and Executive Vice President from 2002 until 2009.
  • In addition to his experience at Mylan, Mr. Borkowski was the former Chief Financial Officer of CareFusion, where he led the IPO.
  • Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Mr.

Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency

Retrieved on: 
Thursday, May 25, 2023
Advanz Pharma, Sorbitol dehydrogenase, Central nervous system, Journal, European Medicines Agency, ATP, Medicine, Cell, Doctor of Philosophy, CNS, Brain cell, Drosophila, EMA, ROS, HIV disease progression rates, Patient, Reactive oxygen species, Sorbitol, Therapy, Adenosine triphosphate, Disease, Pharmaceutical industry, Galactosemia, EU, SORD

Additionally, the Company announced that new data has been published in the Journal of Clinical Investigation on govorestat treatment in models of SORD Deficiency.

Key Points: 
  • Additionally, the Company announced that new data has been published in the Journal of Clinical Investigation on govorestat treatment in models of SORD Deficiency.
  • Applied Therapeutics has partnered govorestat for treatment of SORD Deficiency as well as Galactosemia in Europe with ADVANZ Pharma.
  • The new data on govorestat treatment in models of SORD Deficiency was recently published in the Journal of Clinical Investigation.
  • These findings uncover the molecular and cellular pathophysiology of sorbitol toxicity in SORD neuropathy, and govorestat provides a potential treatment strategy for patients with SORD Deficiency.

Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe

Retrieved on: 
Wednesday, May 24, 2023
Partnership, Omalizumab, Gross metropolitan product, Advanz Pharma, Patient, European Economic Area, Growth, Biosimilar, Fine chemical, Generic drug, IQVIA

Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.

Key Points: 
  • Alvotech will be responsible for development and commercial supply and Advanz Pharma will be responsible for registration and commercialization in Europe.
  • "We are very excited to extend our existing partnership with Advanz Pharma into additional therapeutic areas.
  • “This partnership positions Advanz Pharma as a key future player in European biosimilars.
  • In February 2023 Alvotech and Advanz Pharma announced that the companies had entered into an exclusive agreement for the commercialization of AVT23, a proposed biosimilar to Xolair® (omalizumab).

Nordic Capital acquires majority share in corpuls to support further development of the high-growth med-tech company

Retrieved on: 
Wednesday, April 19, 2023
Telehealth, Partnership, Corpulence index, Health care, SME, Research, Binding site, EUR, Patient, Advanz Pharma, Growth, Defibrillation, Nursing care plan, Medical device, Renewable energy, Pharmaceutical industry, DACH, Nordic Capital

STOCKHOLM, April 19, 2023 /PRNewswire/ -- Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family.

Key Points: 
  • STOCKHOLM, April 19, 2023 /PRNewswire/ -- Nordic Capital has agreed to acquire a majority share in corpuls to support the Company's next phase of growth, in partnership with the founding family.
  • The Company is one of Germany's fastest growing mid-market companies due to an innovative product portfolio and pronounced research & development capabilities.
  • The founding family of corpuls is committed to a long-term partnership with Nordic Capital and will remain invested in the company and represented on the management board.
  • "We are excited to partner with Nordic Capital with the objective of jointly supporting the next stage of corpuls' growth.